Loading...
•
Sep 30, 2025
Bicycle Q3 2025 Earnings Report
Bicycle Therapeutics reported its third quarter 2025 financial results, highlighting progress in its clinical pipeline and a strong cash position.
Key Takeaways
Bicycle Therapeutics reported a net loss of $59.1 million for Q3 2025, an increase from $50.8 million in Q3 2024. Despite the increased loss, the company maintained a strong cash position of $648.3 million, providing a financial runway into 2028. The company also made significant progress in its clinical trials, particularly with zelenectide pevedotin, and strengthened its leadership team.
Net loss for Q3 2025 was $59.1 million, compared to $50.8 million in Q3 2024.
Cash and cash equivalents stood at $648.3 million as of September 30, 2025, excluding a $38.2 million R&D tax credit received in October 2025, providing a financial runway into 2028.
Research and development expenses increased to $58.4 million in Q3 2025, up from $48.3 million in Q3 2024, driven by increased clinical program activities.
The company is seeking broad regulatory feedback for zelenectide pevedotin in metastatic urothelial cancer, with an update on dose selection and potential approval pathway expected in Q1 2026.
Revenue by Segment
Forward Guidance
Bicycle Therapeutics expects to provide an update on dose selection for the Duravelo-2 trial and the potential approval pathway for zelenectide pevedotin in metastatic urothelial cancer in the first quarter of 2026. The company also anticipates initial EphA2 human imaging data in the first half of 2026 and the initiation of the first company-sponsored clinical trial in 2026. Financial runway is expected into 2028.
Positive Outlook
- Update on zelenectide pevedotin's approval pathway expected in Q1 2026.
- Initial EphA2 human imaging data expected in H1 2026.
- First company-sponsored clinical trial expected to initiate in 2026.
- Financial runway extended into 2028.
- Upcoming presentation of BT5528 and BT7480 combination data in H1 2026.
Challenges Ahead
- Dose selection and approval pathway update for zelenectide pevedotin delayed to Q1 2026.
- BT5528 combination data with nivolumab presentation delayed to H1 2026.
- BT7480 combination data with nivolumab presentation delayed to H1 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...